Scarica l'app Stockscreener
47.50
2.84%
-1.39
Dopo l'orario di chiusura:
47.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Challenges - geneonline.com
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Developments - geneonline.com
Learn to Evaluate (MLTX) using the Charts - news.stocktradersdaily.com
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Industry Developments - geneonline.com
MoonLake Immunotherapeutics’ SWOT analysis: nanobody firm’s stock poised for pivotal phase III data - Investing.com South Africa
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Benzinga
IIH interview: Matthias Bodenstedt discusses MoonLake’s capital raising journey, the appeal of SLK and plans for the future - Investors in Healthcare
MoonLake Immunotherapeutics: Strategic Positioning and Promising Clinical Developments Drive Buy Rating - TipRanks
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Focus on Inflammatory Disease Treatments - geneonline.com
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover - MSN
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Focus - geneonline.com
MoonLake Immunotherapeutics (MLTX) Hosts Investor Meetings Amid Merger Speculation | MLTX Stock News - GuruFocus
Stat’s Feuerstein says ‘no imminent acquisition’ of MoonLake Immunotherapeutics - TipRanks
StockWatch: Report of $3B+ Merck Buyout Offer Propels MoonLake Stock Surge - Genetic Engineering and Biotechnology News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
MoonLake Immunotherapeutics Reportedly Exploring Potential Sale Amid Strategic Uncertainty - geneonline.com
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - MSN
MoonLake Immunotherapeutics Elects Directors at AGM - TipRanks
Merck held talks to buy biotech MoonLake for over $3 billion - MSN
These Stocks Moved the Most Today: Nvidia, Tesla, Dollar General, Credo, Ferguson, Moonlake, and More - MSN
MoonLake Immunotherapeutics Reportedly Exploring Potential Sale Amid Industry Speculation - geneonline.com
A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions - insights.citeline.com
MoonLake Immunotherapeutics Reportedly Considering Sale Amid Competitive Pharmaceutical Market Challenges - geneonline.com
MoonLake Immunotherapeutics is for sale? This sounds like a cry for help - statnews.com
Merck's Bold Proposal Sends MoonLake's Shares Climbing - Finimize
Merck made $3B+ offer for MoonLake earlier this yearreport - MSN
Two Biotechs That Could Get an M&A Boost - TheStreet Pro
Merck & Co., Inc. (MRK) Held Talks Over $3 Billion Acquisition of Swiss Biotech Firm MoonLake - MSN
Merck in Talks to Acquire MoonLake Immunotherapeutics for $3 Billion - geneonline.com
MSD rumoured to be eyeing $3bn+ MoonLake takeover - pharmaphorum
MoonLake Immunotherapeutics (MLTX) Surges 25% on Merck Acquisiti - GuruFocus
MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid - Investor's Business Daily
MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest (MLTX) - Seeking Alpha
Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Industry Shifts - geneonline.com
MoonLake Immunotherapeutics Breaks Above 200-Day Moving AverageBullish for MLTX - Nasdaq
MoonLake's (MLTX) 'Outperform' Rating Reiterated by RBC Capital - GuruFocus
MoonLake takeover thesis reemerges after FT report, says Citi - TipRanks
MoonLake Shares Jump On Potential Merck Acquisition Offer - Finimize
MoonLake Immunotherapeutics: Strong Acquisition Interest and Promising Product Pipeline Drive Buy Rating - TipRanks
RBC Capital maintains outperform rating on Moonlake stock By Investing.com - Investing.com India
RBC Capital maintains outperform rating on Moonlake stock - Investing.com
1.08%
2.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):